Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05941741 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

StatusRecruiting
PhasePhase 3
Started2024-01-10
View on ClinicalTrials.gov ↗

Amendment history

2026-05-06
Study Status, Sponsor/Collaborators v6
Primary completion pushed: 2026-12 → 2027-12
2026-03-16
Active, Not Recruiting→Recruiting Study Status, Sponsor/Collaborators, Oversight, Contacts/Locations v5
Trial statusActive, Not Recruiting→Recruiting
Lead sponsorSun Yat-Sen University Cancer Center→Sun Yat-sen University
Study sitesdetails revised at 3 of 3 sites
2025-05-13
Recruiting→Active, Not Recruiting Study Status, Sponsor/Collaborators, Oversight, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Lead sponsorSun Yat-sen University→Sun Yat-Sen University Cancer Center
Study sitesdetails revised at 3 of 3 sites
2024-03-14
Study Status v3
Start dateestimated 2024-01→confirmed 2024-01-10
2024-01-02
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start date2023-12→2024-01
Study sites0→3
2023-11-26
Study Status v1
Primary completion date2026-09→2026-12
Completion date2029-09→2029-12
Start date2023-09→2023-12
2023-07-11
Original filing
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
Trial Details
NCT Number NCT05941741
Lead Sponsor Sun Yat-sen University
Conditions Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Enrollment 380 participants
Start Date 2024-01-10
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-11